Balanced forced-diuresis compared to control as a reno-protective approach in cardiac surgery: secondary outcome of a randomized controlled trial, assessment of neutrophil gelatinase-associated lipocalin levels by Luckraz, Heyman et al.
Luckraz et al. J Cardiothorac Surg          (2021) 16:240  
https://doi.org/10.1186/s13019-021-01620-w
RESEARCH ARTICLE
Balanced forced-diuresis compared 
to control as a reno-protective approach 
in cardiac surgery: secondary outcome 
of a randomized controlled trial, assessment 
of neutrophil gelatinase-associated lipocalin 
levels
Heyman Luckraz1* , Ramesh Giri2, Benjamin Wrigley2, Kumaresan Nagarajan2, Eshan Senanayake2, 
Emma Sharman2, Lawrence Beare3 and Alan Nevill4 
Abstract 
Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a recognised biomarker for acute kidney injury 
(AKI).This study investigated the impact of balanced forced-diuresis using RenalGuard® system (RG), in reducing acute 
kidney injury (AKI) rates and the associated NGAL levels (6-h post-CPB plasma level) post adult cardiac surgery with 
cardiopulmonary bypass (CPB).
Methods: Patients included in the study were at high-risk for AKI post cardiac surgery, namely history of diabetes 
and/or anaemia, e-GFR 20–60 ml/min/1.73  m2, Logistic EuroScore > 5, anticipated CPB time > 120 min. Patients were 
randomized to either RG (n = 110) or managed as per current practice (control = 110). RIFLE-defined AKI rate (based 
on serum creatinine level increase) within first 3 days of surgery and 6-h post CPB NGAL levels were the primary and 
secondary end-points.
Results: Pre and intra-operative characteristics between the two groups were similar (p > 0.05) including the pre-op 
NGAL levels, the oxygen delivery  (ecDO2i) and the carbon dioxide production  (ecVCO2i) during CPB. Patients in the RG 
group had a significantly lower post-operative RIFLE-defined AKI rate compared to control (10% (11/110) v/s 20.9% 
(23/110), p = 0.03). Overall, median 6-h post CPB NGAL levels in patients with AKI were significantly higher than those 
who did not develop AKI (211 vs 150 ng/ml, p < 0.001). Patients managed by balanced forced-diuresis had lower post-
operative NGAL levels (146 vs 178 ng/ml, p = 0.09). Using previously reported NGAL cut-off level for AKI (142 ng/ml), 
binary logistic regression analysis confirmed a beneficial effect of the RG system, with an increased risk of AKI of 2.2 
times in the control group (OR 2.2, 95% CI 1.14–4.27, p = 0.02).
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Background
Neutrophil gelatinase-associated lipocalin (NGAL) was 
first described in 2003 as a urinary marker of ischaemia-
related renal injury [1]. It is as a 25-kD protein cova-
lently bound to gelatinase from human neutrophils [2], 
expressed in stimulated epithelia of kidney (ischemia–
reperfusion injury), stomach and colon (inflammation 
or neoplasia) and in the lungs (chest infections, asthma, 
emphysema [3]. It promotes proliferation in the kidney 
cell tubules via cell modulation, inflammation and neo-
plastic transformation as well as reducing apoptosis [3]. 
After an ischaemic renal insult, NGAL is expressed by 
epithelial cells of the thick ascending limb and collecting 
ducts of the nephrons.
Acute kidney injury (AKI) is well documented after 
cardiac surgery [4]. It is possibly related to the effect 
of vasoconstriction and haemodilution when patients 
are on the cardiopulmonary bypass machine (CPB). 
Although several strategies have been applied to reduce 
AKI [5], the latter still accounts for significant morbidity 
and mortality [6].
Clinical use of NGAL as an early bio-marker of AKI 
has been investigated especially in the paediatric popu-
lation undergoing cardiac surgery where the cardiopul-
monary bypass machine is used [7]. NGAL levels can be 
measured in both urine and plasma [8] and can poten-
tially provide early recognition of AKI so that preventive 
measures could be implemented. One such novel pre-
ventive approach can be provided by the RenalGuard® 
system (RG) (RenalGuard Solutions Inc., Milford, USA). 
This device uses the principle of forced-diuresis and the 
operator can set the desired fluid-replacement level to 
even, positive or negative balance. The various aspects of 
the device have been described in details previously [9]. 
Its use in adult cardiac surgery has also been reported 
and the clinical benefit confirmed [10]. In brief, the RG 
system is a closed-loop system of urine collection via a 
Foley’s catheter and an intravenous fluid administration-
set interfaced through a monitoring console to adjust for 
even, positive or negative fluid balance.
This study reports on the impact of forced-diuresis 
with furosemide and instantaneously-matched even-
balanced intravenous rehydration using the RenalGuard® 
system on its secondary outcomes of the changes in the 
NGAL levels (6-h post CPB) as well as the clinical out-
comes after cardiac surgery.
Materials and methods
Aims and objectives
The primary end-point of the study was recently reported 
and published [10]. It was the RIFLE-defined AKI rate 
(criteria definition—50% increase in pre-op “baseline” 
serum creatinine within first 3 days of surgery) compar-
ing patients managed with the RG system to controls. 
Baseline serum creatinine level was defined as latest 
serum creatinine level available prior to surgery. Second-
ary objectives included changes in plasma NGAL levels 
(Bioporto Diagnostics, Hellerup, Denmark) at 6-h post-
CPB as well as pre-CPB NGAL levels and post-operative 
complications.
Ethical approval
This study (KIDNEY) was reviewed and approved by the 
Institutional Research Committee (16CARD13) prior to 
seeking Ethical committee (16/NI/0246,  2nd December 
2016) approval and was registered on ClinicalTrials.gov 
website (NCT02974946). The study was also supported 
by the National Institute of Healthcare Research, Clinical 
Research Network, United Kingdom (NIHR ID: 32769). 
All recruited patients gave written informed consent to 
partake in the study. Trial patients were treated according 
to the Declaration of Helsinki 2013.
Inclusion criteria
Patients with one (or more) of the following risk fac-
tors for AKI were recruited for this study: (1) diabetics 
(insulin or non-insulin dependent diabetes mellitus), (2) 
haemoglobin level of 12.5 g/dl or below, (3) Logistic Euro-
score of 5 or above, (4) estimated glomerular filtration 
rate (eGFR) of 20–60  mL/min/1.73   m2 and (5) cardiac 
procedures when CPB-time was likely to exceed 120 min. 
Recruited patients underwent one of the following proce-
dures: isolated coronary artery bypass grafting (CABG), 
isolated valve surgery (aortic valve replacement—AVR, 
mitral valve replacement—MVR, mitral valve repair—
MV repair) or combined procedures (CABG, AVR, MV 
repair, tricuspid valve repair, MVR, Cox-Maze IV atrial 
fibrillation ablation, ascending aorta replacement, aortic 
Conclusions: Overall, the 6-h post-CPB plasma NGAL levels were significantly higher in patients who developed AKI. 
Patients managed with the novel approach of balanced forced-diuresis, provided by the RenalGuard® system, had a 
lower AKI rate and lower NGAL levels indicating a lesser degree of renal tissue injury.
Trial registration ClinicalTrials.gov website, NCT02974946, https:// clini caltr ials. gov/ ct2/ show/ NCT02 974946.
Keywords: Acute kidney injury, Cardiac surgery, RenalGuard® system, Neutrophil gelatinase-associated lipocalin, 
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root surgery, left ventricular aneurysmectomy and myx-
oma surgery in various combinations).
Intervention
Consented patients were randomized using sealed 
opaque envelopes system generated by a research inde-
pendent person in the research and development depart-
ment. Management of patients randomised to the 
RenalGuard® system has been previously described [10] 
and included instantaneously-matched balanced forced-
diuresis with furosemide and intravenous rehydration 
with Hartmann’s solution. Patients in the control group 
were managed as per current medical practice without 
forced-diuresis with intravenous furosemide in the OR. 
Otherwise, the management of the patients was similar 
including the anaesthetic technique and cardiopulmo-
nary bypass run including the need for inotropic support 
to maintain a MAP (mean arterial pressure) > 65 mmHg. 
CPB-flow was maintained at cardiac index of 2.4  l/min/
m2. Oxygen delivery  (ecDO2i) and  CO2 production 
 (ecVCO2i) during the CPB were monitored using the Sys-
tem M4 (Spectrum Medical, Gloucester, UK). Post-oper-
atively both groups of patients were transferred to CICU.
NGAL test
The NGAL levels were assessed from plasma (ethylene 
diamine tetra-acetic acid—EDTA—tube) collected prior 
to the start of cardiac surgery and at 6-h post cessation 
of CPB while the patient was recovering on the CICU. 
Specimens were centrifuged at 2380  g for 10  min at 
4 °C on the day of receipt, to pellet cellular material and 
the supernatants aliquoted and stored at − 80  °C until 
analysed. The NGAL test was a quantitative particle-
enhanced turbimetric immune-assay (PETIA) using the 
BioPorto Kit (BioPorto Diagnostics A/S, Gentofte, Den-
mark) and the Abbott Architect C16000 analyser (Abbott 
Diagnostics, Chicago, USA).
Power calculations and statistical analyses
Based on the data from the department’s cardiac surgery 
database and previous publications [6], 110 patients per 
group were deemed adequate to achieve the primary 
end-point (RIFLE defined AKI rate) with a power of 0.8 
and an alpha of 0.05.
Categorical data are expressed as percentages and dif-
ferences between the two groups assessed using the X2 
test of independence. Continuous variables are expressed 
as mean (standard deviation—SD) or median (mini-
mum, maximum) for normally and skewed distributed 
data respectively. Group comparison was carried out 
using two-tailed t-test or Mann–Whitney U test accord-
ingly. Adopting a previously reported NGAL cut-off level 
(142  ng/ml) for AKI, binary logistic regression analysis 
was used to assess the beneficial effect of the RG system. 
The factors included in the model were age, gender, eth-
nic origin, history of diabetes, left ventricular ejection 
fraction, pre-operative creatinine level, pre-operative 
NGAL level, pre-op eGFR level, Log EuroScore, STS 
Score, study group (RG vs. control), CVP, MAP and lac-
tate levels in OR prior to start of surgery, CPB duration, 
procedure performed, urine volume produced in OR, 
CVP, MAP and lactate levels on admission to CICU and 
blood transfusion. The tests were considered significant 
at p < 0.05. SPSS version 26.0 (IBM SPSS statistics 26) was 
used for statistical analyses.
Two patients who were randomized to RG group could 
not be catheterized per urethrally at the start of the oper-
ation and had a supra-pubic catheter inserted at the end 
of the procedure and hence were not connected to the 
RG system. Additionally, two patients in the RG group 
and one patient from the control group had their surgery 
cancelled and therefore did not have post-operative data. 
All patients’ data were analysed on an intention- to-treat 
basis.
Patients were recruited from 1st March 2017 to 4th 
September 2019 as shown in the Consolidated Standards 
of Reporting Trials (CONSORT) flow diagram (Fig. 1).
Results
Two hundred and twenty patients undergoing cardiac 
surgery were recruited to the study (110 patients per 
group). The patients’ pre and intra-operative characteris-
tics are detailed in Table 1 and were not significantly dif-
ferent between the two groups.
The average oxygen delivery  (ecDO2i) and  CO2 pro-
duction  (ecVCO2i) during the CPB were maintained at 
similar levels for the two groups, Table  1. Likewise the 
MAP and the central venous pressure (CVP) were not 
significantly different during CPB being 57.5 (8.9) vs 57.5 
(9.4)  mmHg and 3 (4.9) vs 3 (4.6)   cmH2O respectively. 
Although the median lactate levels during surgery were 
statistically different between the two groups, these levels 
were not clinically significantly different, being around 
2 mmol/L (Table 1).
Post-operative AKI rates (as per RIFLE definition) were 
significantly lower in RG group as compared to control 
(10% (11/110) v/s 20.9% (23/110), p = 0.025) and has, pre-
viously, been reported in details [10].
The secondary end-points confirmed that mean 
volumes of urine produced during surgery were sig-
nificantly higher in RG group (2366 ± 877  ml v/s 
765 ± 549  ml, p < 0.001). Likewise at 6-h post- CICU 
admission, patient in the RG group produced a higher 
volume of urine (1911 ± 904  ml v/s 911 ± 407  ml, 
p < 0.001). Moreover, the median 6-h post-CPB NGAL 
levels were significantly higher in the patients who 
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developed AKI (211 vs 150 ng/ml, p < 0.001). Generally, 
patients managed with balanced forced-diuresis had 
lower post-op median NGAL levels (146 vs 178 ng/ml, 
p = 0.09).
When previously reported NGAL cut-off level (142 ng/
ml) for AKI was used [11], binary logistic regression 
analysis confirmed a beneficial effect of the use of the 
RG system, with an increased risk of AKI of 2.2 times in 
the control group (OR 2.2, 95% CI 1.14–4.27, p = 0.02). 
Higher levels of 6-h post-op NGAL were also associated 
with pre-operative NGAL level, Log EuroScore and being 
in the control group as noted above. There was no sig-
nificant direct correlation between the serum creatinine 
levels and the plasma NGAL levels pre-operatively or 
post-operatively (Table 2).
During the post-operative recovery phase, there was 
no significant difference in incidence of atrial fibrillation 
rate, blood transfusions and infections (Table 1) between 
the 2 groups. One patient in RG group and two patients 
in control group died prior to hospital discharge with the 
cause of death not related to the use of device.
Discussion
This study confirmed that, in patients at-risk of AKI post 
cardiac surgery, balanced forced-diuresis as provided by 
the RenalGuard® system reduces the AKI rate and the 
associated 6-h post-CPB NGAL levels.
NGAL has been likened to the troponin-equivalent of 
the kidneys for AKI detection. It is a reflection of tissue 
damage within the renal system [1]. A rise in the NGAL 
Patients underwent surgery during 
study period =1902
Inclusion criteria met by 1245
patients 
Patients not eligible = 657
Patients not recruited due to 
participation in other studies or not 
possible to discuss research with 
patient within appropriate time = 940
Patients recruited to the study = 220
Patients in RG group = 110 Patients in Control group = 110
Patients with 6-hr NGAL levels = 108
Patients for data analysis = 110
Patients with 6-hr NGAL levels = 105
Patients for data analysis = 110
Patients screened by research 
team = 305
Excluded
Patients refused = 22
Surgeons refused = 16
Operation changed to OPCAB or 
eGFR improved on admission = 15
Other reasons = 32
Fig. 1 CONSORT flow diagram for recruitment
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levels within the first few hours of the insult has pro-
vided the possibility of an early diagnosis of AKI post-
CPB. Some researchers have even advocated the use of 
both the pre-operative and post-operative NGAL lev-
els as a means to stratify clinical management strategies 
[12]. Both urinary and plasma NGAL levels have been 
evaluated [8, 13] and currently, plasma NGAL is emerg-
ing as the most reliable option [14]. In the current study, 
patients who developed AKI had significantly higher 
6 h-post CPB NGAL levels. The use of the RG system was 
associated with lower NGAL levels post-op but it did not 
reach statistical significance. This could be a reflection of 
the fact the study was powered to assess AKI rates rather 
than the 6 h-post CPB NGAL levels. A larger size study 
would be needed to confirm these NGAL-level findings. 
Based on the current data available from this study, a 
sample size of 200 patients per group would be needed 
to test this null hypothesis (assessment of a difference in 
the 6-h post-CPB NGAL levels between RG and control) 
with a power of 0.8 and an alpha of 0.05.
It is important to ascertain that organ perfusion is 
optimized during the CPB run. There is good evidence 
to suggest that AKI during CPB is related to significant 
impairment of renal oxygenation due to renal vasocon-
striction and haemodilution [15]. Traditionally, MAP, 
CVP, CPB flow-rates and overall blood oxygen satura-
tion had been used as indicators of tissue perfusion but 
more recently measurement of oxygen delivery has pro-
vided an improved level of tissue perfusion assessment. 
Ranucci et  al. have reported that oxygen delivery levels 
below 272 ml/min/m2 was the strongest predictor of AKI 
[16]. Similar findings were reported by Rasmussen et al. 
who reported at least a 2.5 times increase in AKI rate 
when  ecDO2i was less than 272  ml/min/m2 [17]. It has 
also been reported that  ecVCO2i level exceeding 60 ml/
min/m2 was associated with hyperlactataemia indicating 
Table 1 Pre, peri and post-operative characteristics of patients in the two groups
Table showing the patients’ characteristics for the two groups along with the intra-operative data and post-operative complications rates
e-GFR estimated glomerular filtration rate, NGAL neutrophil gelatinase-associated lipocalin, LVEF left ventricular ejection fraction, ecDO2i oxygen delivery, ecVCO2i CO2 
production during the CPB, XCT cross clamp time, CICU cardiac intensive care unit
a Denotes mean (SD)
b Denotes median (minimum, maximum)
RG group (n = 110) Control group (n = 110) p value
Pre-op  creatininea, micromol/L 99.0 (28.2) 98.3 (34.7) 0.29
Pre-op  eGFRa, ml/min/1.73m2 66.5 (17.2) 68.2 (20.3) 0.47
Pre-op  Haemoglobina, g/L 135 (16) 134 (18) 0.72
Logistic  EuroScoreb 3.8 (0.9, 67.4) 3.2 (0.9, 32.5) 0.3
Agea, years 67.8 (9.3) 67.0 (9.2) 0.33
Pre-op NGAL  levelb, (ng/ml) 83 (19, 202) 86(15,459) 0.64
Male, (n, %) 87, 79% 84, 76% 0.63
Non-diabetics, (n, %) 30, 27% 30, 27% 0.66
Impaired LVEF, (n, %) 51, 46% 38, 34% 0.14
Urgent surgery, (n, %) 34, 31% 24, 22% 0.13
Combined operations, (n, %) 40,37% 31, 28% 0.38
ecDO2i
a, ml/min/m2 300 (52) 300 (52) 0.73
ecVCO2
a, ml/min/m2 70 (24) 71 (21) 0.92
XCT  timea, mins 84 (40) 79 (42) 0.25
Serum lactate during  surgeryb, mmol/L 1.97 (0.78,5.00) 1.80 (0.87,4.98)  < 0.01
Serum lactate on  CICUb, mmol/L 1.8 (0.60, 6.80) 1.7 (0.6, 8.70) 0.14
CICU  stayb, hours 27 (16, 410) 28 (8, 486) 0.92
Atrial Fibrillation, (n/total, %) 12/108, (11%) 10/108, (9%) 0.62
Blood transfusion, (n/total, %) 29/108, (27%) 21/109, (19%) 0.16
Infection, (n/total,%) 10/108, (9%) 8/108, (7%) 0.59
In-hospital survival, (n/total, %) 109/110 (99%) 108/110 (98%) 0.56
Table 2 Correlation between serum creatinine level and plasma 
NGAL level
a Denotes the ratio of the post-op change of the level from baseline
Pearson correlation RG group Control group
Pre-op creatinine and pre-op NGAL 0.476 0.43
RIFLE creatinine and 6-h NGAL (post-op) 0.518 0.587
Creatinine and NGAL  changesa 0.405 0.163
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poor tissue perfusion [18]. In this study, not only the 
MAP, CVP and CPB flow-rates but also the  ecDO2i and 
 ecVCO2i were maintained at appropriate and similar lev-
els for both groups ensuring adequate organ perfusion 
(Table  1). During this study, the  ecDO2i/ecVCO2i ratio 
was maintained above 5, ensuring effective organ perfu-
sion during the CPB. Furthermore, the median lactate 
levels during CPB and within the first 6 h on the CICU 
were less 2 mmol/L for both groups (Table 1).
The mechanisms by which this balanced forced-diu-
resis, in the RG group, would protect the kidneys is not 
entirely clear but could be related to the fact that furo-
semide prevents renal hypoxia at the level of loop of 
Henle by inhibiting the sodium potassium chloride 
co-transporter (NKCC2) channels present on the api-
cal membrane of the thick ascending limb (TAL) [19] 
whilst the forced-diuresis prohibits the build-up of casts 
within the renal tubules which is well recognized in acute 
tubular necrosis. The patients in the RG group produced 
three times as much urine during surgery, and twice as 
much within the first 6 h on CICU, as compared to con-
trols. This constant high-volume diuresis could poten-
tially prevent the clogging of the renal tubules but could 
lead to intra-vascular dehydration of the patient. Thus, it 
is imperative to maintain real-time instantaneous fluid 
replacement as provided by the RG system.
As expected, there was no significant correlation 
between the plasma NGAL levels and the serum creati-
nine levels in the two groups. This is hardly surprising as 
the serum concentration of creatinine represents a bal-
ance between its production (related to muscle mass) 
and the glomerular filtration rate (GFR) while the plasma 
NGAL is reflective of ischaemic renal insult leading to 
NGAL being expressed by epithelial cells of the thick 
ascending limb and collecting ducts of the nephrons. 
Serum creatinine level is an insensitive, non-specific and 
delayed marker of acute kidney injury and the level is 
influenced by several factors such as muscle mass, muscle 
damage, nutritional status and body surface area as well 
as medications which affect the glomerular filtration rate 
[20]. Plasma NGAL however is a more sensitive marker 
of acute kidney injury and may become in the near future 
the new gold standard for assessment of AKI.
Finally, despite the large volume diuresis with the cor-
responding volume fluid replacement that the RG group 
had as compared to controls, there was no significant 
difference in the requirements for blood transfusion 
between the two groups. Similarly, the rates of atrial 
fibrillation as well as infections were similar in both 
groups. This confirms that the use of balanced forced-
diuresis is safe in this group of surgical patients.
This study now provides additional information (second-
ary outcome) regarding the possible mechanisms of the 
renal-protective effect of a novel therapy using balanced 
forced-diuresis, provided by the RenalGuard® system, by 
reducing ischaemic kidney injury as reflected in the lower 
6 h-post CPB NGAL levels. It has already reported reduced 
AKI rates when the RenalGuard® system was used [10].
Limitations
This is a single-centre study and is now reporting on the 
secondary outcomes. The study was powered for the pri-
mary end-point only. Additionally, it was not possible to 
blind the attending clinical personnel to the study.
Conclusion
Overall, the 6-h post-CPB plasma NGAL levels were sig-
nificantly higher in patients who developed AKI. Renal-
Guard® system reduces the 6 h-post CPB NGAL levels by 
using the principle of balanced forced-diuresis. Patients 
managed with this novel approach (balanced forced-diure-
sis) had a lower AKI rate and lower NGAL levels indicating 
a lesser degree of renal tissue injury.
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